Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
Metrics: PDF 1322 views | HTML 2948 views | ?
Areumnuri Kim1,2, Ki Moon Seong2, Hye Jin Kang3, Sunhoo Park1,2,4, Seung-Sook Lee1,2,4
1Laboratory of Experimental Pathology, National Radiation Emergency Medical Center, Seoul, Korea
2Laboratory of Radiation Exposure & Therapeutics, National Radiation Emergency Medical Center, Seoul, Korea
3Division of Hematology/Oncology, Department of Internal Medicine, Seoul, Korea
4Departments of Pathology, Korea Institute of Radiological & Medical Science, Seoul, Korea
Seung-Sook Lee, e-mail: [email protected]
Keywords: B cell receptor signaling, Lyn, bortezomib resistance, mantle cell lymphoma, dasatinib
Received: May 27, 2015 Accepted: August 22, 2015 Published: October 21, 2015
Although proteasome inhibition with bortezomib (BTZ) is a validated treatment for relapsed or refractory mantle cell lymphoma (MCL), many patients show resistance to BTZ. However, the molecular mechanism of BTZ resistance in MCL has not been elucidated. In the present study, we investigated BTZ-resistant MCL cells in vitro and in vivo. We demonstrate that BTZ-resistant MCL cells showed highly increased expression of the B-cell receptor (BCR) components CD79A and CD19. Activation of the BCR signaling pathway enhanced the activity of Src family kinases (SFKs), especially Lyn, and downstream kinases PI3K/AKT/mTOR in BTZ-resistant MCL cells. Depletion of CD79A and Lyn significantly reduced several kinase activities involved in PI3K signaling, leading to inhibition of proliferation. In addition, the SFKs inhibitor dasatinib inhibited the proliferation of BTZ-resistant cells, preventing the binding of CD19 with Lyn and PI3K p85. We also verified our findings with the mouse xenograft tumor model. Dasatinib treatment significantly decreased tumor size in the mouse bearing BTZ-resistant MCL cells, but not in the mouse bearing BTZ-sensitive MCL cells. Collectively, our data show that overexpression of the BCR and its activated signaling confers BTZ resistance in MCL cells. Thus, targeting BCR signaling with dasatinib could be a novel therapeutic approach for patients with MCL that has relapsed or is refractory to treatment with BTZ.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.